Can BD Medical Drive Becton, Dickinson's (BDX) Q2 Earnings?
Zacks Investment Research | May 03, 2019 08:29AM ET
Becton, Dickinson and Company’s (NYSE:BDX) , popularly known as BD, second-quarter fiscal 2019 results are scheduled to release on May 9, before market opens. While the results are likely to show steady growth in the core BD Medical segment, weakness in BD Life Sciences may partially mar results.
Notably, BD has a positive average surprise of 1% in the trailing four quarters.
Which Way Are Estimates Treading?
For the quarter to be reported, the Zacks Consensus Estimate for BD’s earnings per share is pegged at $2.59, suggesting a year-over-year decline of 2.3%. The same for revenues stands at $4.24 billion, indicating an increase of 0.5%.
Let’s see how things are shaping up prior to the earnings release.
BD Medical Likely to Drive Q2 Earnings
BD Medical, one of the major revenue drivers of the company, is expected to drive fiscal second-quarter results. Strong year-over-year growth in revenues from needles, syringes and intravenous catheters for medication delivery, prefilled IV flush syringes, syringes and pen needles for diabetes care and others are likely to boost the segment.
It is encouraging to note that for the second quarter, the Zacks Consensus Estimate for the segment’s revenues is pegged at $2.21 billion, suggesting a rise of 1.7% year over year.
Notably, BD recently launched two cloud-based applications, BD HealthSight Data Manager and BD HealthSight Diversion Analytics, which are likely to contribute to the segment’s results.
Additionally, management expects the sub-segments ??? Medical Surgical Solutions, Pharmaceutical Systems and Diabetes Care — to drive the unit.
The Zacks Consensus Estimate for Medical Surgical Solutions’ fiscal second-quarter revenues stands at $975 million, calling for a year-over-year rise of 1.8%. The growth is expected to be driven by strength in vascular access and infusion disposables.
For Pharmaceutical Systems, the Zacks Consensus Estimate for second-quarter revenues is pinned at $344 million, suggesting a year-over-year rise of 12.8%.
Management expects strong demand for core products and increased customer ordering.
For Diabetes Care, the Zacks Consensus Estimate for second-quarter revenues stands at $262 million, suggesting a drop of 8.7% year over year.
Timing of orders in the United States and the EMEA is likely to affect sales in the sub-segment.
Get The News You Want
Read market moving news with a personalized feed of stocks you care about.
Get The App
Becton, Dickinson and Company Price and EPS Surprise
Original post
Written By:
Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Get The News You Want